Paper · 42985628

Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus.

Khan T and 6 others. Cureus, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus. Papers, record 42985628. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42985628

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus.
Journal: Cureus
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42985628/
DOI: https://doi.org/10.7759/cureus.117491
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13734297/
The journal: https://conductscience.org/library/journal-index/101596737
Revised in PubMed: 2026-11-06

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Khan T	Tahseer
2	Tirmizi SB	Syeda Batool
3	Shehzad A	Aamir
4	Shamim A	Arslan
5	Ramzan Z	Zara
6	Raza A	Ahsan
7	Khan S	Sarah

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	41,358,893	2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026.	Diabetes Care	2026	https://conductscience.org/library/papers/41358893	PubMed
2	41,430,716	Personalized MASLD and liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices.	Diabetol Metab Syndr	2025	https://conductscience.org/library/papers/41430716	PubMed
3	19,067,533	The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects.	Metab Syndr Relat Disord	2008	https://conductscience.org/library/papers/19067533	PubMed
4	41,650,125	Adoption and validation of the European Association for the Study of the Liver algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease in low-resource South Asian settings.	PLoS One	2026	https://conductscience.org/library/papers/41650125	PubMed
5	38,626,948	TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.	BMJ	2024	https://conductscience.org/library/papers/38626948	PubMed
6	40,348,110	Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes.	Clin Gastroenterol Hepatol	2025	https://conductscience.org/library/papers/40348110	PubMed
7	8,870,764	Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity.	Acad Emerg Med	1996	https://conductscience.org/library/papers/8870764	PubMed
8	34,166,721	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.	J Hepatol	2021	https://conductscience.org/library/papers/34166721	PubMed
9	37,252,406	The Prevalence of Advanced Liver Fibrosis Among Patients With Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia.	J ASEAN Fed Endocr Soc	2023	https://conductscience.org/library/papers/37252406	PubMed
10	38,716,213	Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population.	Transl Gastroenterol Hepatol	2024	https://conductscience.org/library/papers/38716213	PubMed

1 to 10 of 24

See all 24 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42985628

GET https://conductscience.org/api/papers/v1/42985628/references?page=2

API reference For AI assistants